Log in

NYSEAMERICAN:OCX - OncoCyte Stock Price, Forecast & News

$2.51
+0.07 (+2.87 %)
(As of 02/18/2020 05:04 AM ET)
Today's Range
$2.42
Now: $2.51
$2.60
50-Day Range N/A
52-Week Range
$1.50
Now: $2.51
$5.60
Volume190,522 shs
Average Volume362,810 shs
Market Capitalization$130.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$130.45 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) announced its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). View OncoCyte's Earnings History.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for OncoCyte.

What price target have analysts set for OCX?

2 brokers have issued twelve-month price targets for OncoCyte's stock. Their forecasts range from $7.00 to $7.75. On average, they expect OncoCyte's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 193.8% from the stock's current price. View Analyst Price Targets for OncoCyte.

What is the consensus analysts' recommendation for OncoCyte?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

News headlines about OCX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for OncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,160,000 shares, a decrease of 7.2% from the January 15th total of 1,250,000 shares. Based on an average trading volume of 290,900 shares, the days-to-cover ratio is presently 4.0 days. Currently, 2.5% of the company's shares are sold short. View OncoCyte's Current Options Chain.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the folowing people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (3.92%), State Street Corp (0.84%), P.A.W. Capital Corp (0.48%), Penbrook Management LLC (0.34%), Barclays PLC (0.33%) and Mesirow Financial Investment Management Inc. (0.31%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Institutional Ownership Trends for OncoCyte.

Which institutional investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, AQR Capital Management LLC and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for OncoCyte.

Which institutional investors are buying OncoCyte stock?

OCX stock was bought by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Penbrook Management LLC, Barclays PLC, Oxford Asset Management LLP, Virtu Financial LLC, State Street Corp and UBS Group AG. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Insider Buying and Selling for OncoCyte.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $2.51.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $130.45 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

What is OncoCyte's official website?

The official website for OncoCyte is http://www.oncocyte.com/.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.


MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel